Zymeworks Inc. (ZYME)

USD 12.74

(-4.71%)

Market Cap (In USD)

877.49 Million

Revenue (In USD)

76.01 Million

Net Income (In USD)

-118.67 Million

Avg. Volume

739.81 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
7.97-17.7
PE
-
EPS
-
Beta Value
1.157
ISIN
US98985Y1082
CUSIP
98985W102
CIK
1403752
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Kenneth H. Galbraith C.A.
Employee Count
-
Website
https://www.zymeworks.com
Ipo Date
2017-04-28
Details
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.